Brief: Theravance Biopharma Inc - Co And Mylan Settle With Cipla Over Yupelri Inhalation Solution - SEC Filing
20/08/2025 13:15
Theravance Biopharma Inc TBPH.O: THERAVANCE BIOPHARMA INC - CO AND MYLAN SETTLE WITH CIPLA OVER YUPELRI INHALATION SOLUTION - SEC FILING THERAVANCE BIOPHARMA- CO, MYLAN GRANTED CIPLA LICENSE TO MANUFACTURE & MARKET GENERIC VERSION OF YUPELRI IN US ON/AFTER APRIL 23, 2039 Source text: [ID:n0001104659-25-080470] Further company coverage: TBPH.O
Recent news on Theravance Biopharma
See all newsTheravance Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Brief: Theravance Biopharma Q2 Operating Income USD -8.277 Million
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions